Cargando…

p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation

p21-activated kinases (Paks) are serine/threonine protein kinases involved in biological events linked to malignant tumor progression. In this study, expression of Pak1, p-Pak2 Ser(20), Pak4, pPak4 Ser(474) in 21 normal endometrium, 16 hyperplastic endometrium without atypia, 17 atypical complex hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Siu, Michelle K. Y., Kong, Daniel S. H., Ngai, Sheila Y. P., Chan, Hoi Yan, Jiang, Lili, Wong, Esther S. Y., Liu, Stephanie S., Chan, Karen K. L., Ngan, Hextan Y. S., Cheung, Annie N. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517872/
https://www.ncbi.nlm.nih.gov/pubmed/26218748
http://dx.doi.org/10.1371/journal.pone.0133467
_version_ 1782383253285502976
author Siu, Michelle K. Y.
Kong, Daniel S. H.
Ngai, Sheila Y. P.
Chan, Hoi Yan
Jiang, Lili
Wong, Esther S. Y.
Liu, Stephanie S.
Chan, Karen K. L.
Ngan, Hextan Y. S.
Cheung, Annie N. Y.
author_facet Siu, Michelle K. Y.
Kong, Daniel S. H.
Ngai, Sheila Y. P.
Chan, Hoi Yan
Jiang, Lili
Wong, Esther S. Y.
Liu, Stephanie S.
Chan, Karen K. L.
Ngan, Hextan Y. S.
Cheung, Annie N. Y.
author_sort Siu, Michelle K. Y.
collection PubMed
description p21-activated kinases (Paks) are serine/threonine protein kinases involved in biological events linked to malignant tumor progression. In this study, expression of Pak1, p-Pak2 Ser(20), Pak4, pPak4 Ser(474) in 21 normal endometrium, 16 hyperplastic endometrium without atypia, 17 atypical complex hyperplasia and 67 endometrial cancers was assessed by immunohistochemistry and correlated with clinicopathological parameters. We also accessed the proliferative role and downstream targets of Pak1 in endometrial cancer. Pak1 was expressed in cytoplasm whereas Pak4 and p-Pak4 were expressed in both cytoplasm and nucleus of endometrial tissues. In normal endometrium, significantly higher Pak1 (P = 0.028) and cytoplasmic p-Pak2 (P = 0.048) expression was detected in proliferative endometrium than secretory endometrium. Pak1, cytoplasmic and nuclear Pak4 and nuclear p-Pak4 was significantly overexpressed in endometrial cancer when compared to atrophic endometrium (all P<0.05). Moreover, type I endometrioid carcinomas showed significantly higher Pak1 expression than type II non-endometrioid carcinomas (P<0.001). On the other hand, Pak1, Pak4 and p-Pak4 expression negatively correlated with histological grade (all P<0.05) while p-Pak2 and cytoplasmic Pak4 expression inversely correlated with myometrial invasion (all P<0.05). Furthermore, patients with endometrial cancers with lower cytoplasmic Pak4 expression showed poorer survival (P = 0.026). Multivariate analysis showed cytoplasmic Pak4 is an independent prognostic factor. Functionally, knockdown of Pak1, but not Pak4, in endometrial cancer cell line led to reduced cell proliferation along with reduced cyclin D1, estrogen receptor (ERα) and progestogen receptor (PR) expression. Significant correlation between Pak1 and PR expression was also detected in clinical samples. Our findings suggest that Pak1 and cytoplasmic p-Pak2 may promote cell proliferation in normal endometrium during menstral cycle. Pak1, cytoplasmic and nuclear Pak4 and nuclear p-Pak4 are involved in the pathogenesis of endometrial cancer especially in postmenopausal women. Pak1 promote endometrial cancer cell proliferation, particular in type I endometrioid carcinoma. Cytoplasmic Pak4 can be potential prognostic marker in endometrial cancer.
format Online
Article
Text
id pubmed-4517872
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45178722015-07-31 p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation Siu, Michelle K. Y. Kong, Daniel S. H. Ngai, Sheila Y. P. Chan, Hoi Yan Jiang, Lili Wong, Esther S. Y. Liu, Stephanie S. Chan, Karen K. L. Ngan, Hextan Y. S. Cheung, Annie N. Y. PLoS One Research Article p21-activated kinases (Paks) are serine/threonine protein kinases involved in biological events linked to malignant tumor progression. In this study, expression of Pak1, p-Pak2 Ser(20), Pak4, pPak4 Ser(474) in 21 normal endometrium, 16 hyperplastic endometrium without atypia, 17 atypical complex hyperplasia and 67 endometrial cancers was assessed by immunohistochemistry and correlated with clinicopathological parameters. We also accessed the proliferative role and downstream targets of Pak1 in endometrial cancer. Pak1 was expressed in cytoplasm whereas Pak4 and p-Pak4 were expressed in both cytoplasm and nucleus of endometrial tissues. In normal endometrium, significantly higher Pak1 (P = 0.028) and cytoplasmic p-Pak2 (P = 0.048) expression was detected in proliferative endometrium than secretory endometrium. Pak1, cytoplasmic and nuclear Pak4 and nuclear p-Pak4 was significantly overexpressed in endometrial cancer when compared to atrophic endometrium (all P<0.05). Moreover, type I endometrioid carcinomas showed significantly higher Pak1 expression than type II non-endometrioid carcinomas (P<0.001). On the other hand, Pak1, Pak4 and p-Pak4 expression negatively correlated with histological grade (all P<0.05) while p-Pak2 and cytoplasmic Pak4 expression inversely correlated with myometrial invasion (all P<0.05). Furthermore, patients with endometrial cancers with lower cytoplasmic Pak4 expression showed poorer survival (P = 0.026). Multivariate analysis showed cytoplasmic Pak4 is an independent prognostic factor. Functionally, knockdown of Pak1, but not Pak4, in endometrial cancer cell line led to reduced cell proliferation along with reduced cyclin D1, estrogen receptor (ERα) and progestogen receptor (PR) expression. Significant correlation between Pak1 and PR expression was also detected in clinical samples. Our findings suggest that Pak1 and cytoplasmic p-Pak2 may promote cell proliferation in normal endometrium during menstral cycle. Pak1, cytoplasmic and nuclear Pak4 and nuclear p-Pak4 are involved in the pathogenesis of endometrial cancer especially in postmenopausal women. Pak1 promote endometrial cancer cell proliferation, particular in type I endometrioid carcinoma. Cytoplasmic Pak4 can be potential prognostic marker in endometrial cancer. Public Library of Science 2015-07-28 /pmc/articles/PMC4517872/ /pubmed/26218748 http://dx.doi.org/10.1371/journal.pone.0133467 Text en © 2015 Siu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Siu, Michelle K. Y.
Kong, Daniel S. H.
Ngai, Sheila Y. P.
Chan, Hoi Yan
Jiang, Lili
Wong, Esther S. Y.
Liu, Stephanie S.
Chan, Karen K. L.
Ngan, Hextan Y. S.
Cheung, Annie N. Y.
p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation
title p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation
title_full p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation
title_fullStr p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation
title_full_unstemmed p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation
title_short p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation
title_sort p21-activated kinases 1, 2 and 4 in endometrial cancers: effects on clinical outcomes and cell proliferation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517872/
https://www.ncbi.nlm.nih.gov/pubmed/26218748
http://dx.doi.org/10.1371/journal.pone.0133467
work_keys_str_mv AT siumichelleky p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation
AT kongdanielsh p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation
AT ngaisheilayp p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation
AT chanhoiyan p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation
AT jianglili p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation
AT wongesthersy p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation
AT liustephanies p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation
AT chankarenkl p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation
AT nganhextanys p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation
AT cheungannieny p21activatedkinases12and4inendometrialcancerseffectsonclinicaloutcomesandcellproliferation